血液・腫瘍内科

• Miura K, Iriyama N, Hatta Y, Takei M. Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. Expert Rev Precis Med Drug Dev 2021:1–13. doi:10.1080/23808993.2021.1903314.
• Miura K, Tsujimura H, Masaki Y, Iino M, Takizawa J, Maeda Y, et al. Consolidation with 90Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma. Hematol Oncol 2020. doi:10.1002/hon.2809.
• Miura K, Konishi J, Miyake T, Makita M, Hojo A, Masaki Y, et al. A Host‐Dependent Prognostic Model for Elderly Patients with Diffuse Large B‐Cell Lymphoma. Oncologist 2017;22:554–60. doi:10.1634/theoncologist.2016-0260.
• 悪性リンパ腫治療マニュアル（共著）（南江堂）
• EBM血液疾患の治療（共著）（中外医学社）

Iizuka K, Morishita S, Nishizaki Y, Iizuka Y, Iriyama N, Ochiai T, Yanagisawa N, Yasuda H, Ando J, Gotoh A, Takei M, Hatta Y, Nakamura H, Nakayama T, Komatsu N. von Willebrand factor activity levels are influenced by drive mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. Eur J Haematol. 2022; 109(6):779-786

Shimon Otake, Tomoyuki Sasaki, Toshiaki Shirai, Nagaharu Tsukiji, Shogo Tamura, Katsuhiro Takano, Yukio Ozaki, Katsue Suzuki-Inoue. CLEC-2 stimulates IGF-1 secretion from podoplanin-positive stream cells and positively regulates erythropoiesis in mice.

Journal of Thrombosis and Haemostasis. 2021; 19(6):1572-1584

Shimon Ohtake, Hiromichi Takahashi, Masaru Nakagawa, Yoshihito Uchino, Katsuhiro Miura, Noriyoshi Iriyama, Tomohiro Nakayama, Yoshihiro Hatta, Masami Takei. One percent chlorhexidine-alcohol for preventing central venous catheter-related infection during intensive chemotherapy for patients with haematologic malignancies. Journal of infection and chemotherapy. 2018; 24(7):544-548

Kazuya Kurihara, Noriyoshi Iriyama, Katsuhiro Miura, Yoshihito Uchino, Hiromichi Takahashi, Masaru Nakagawa, Kazuhide Iizuka, Takashi Hamada, Takashi Koike, Yoshihiro Hatta, Tomohiro Nakayama, Masami Takei. MPC‑1 expression in myeloma cells is associated with the efficacy of bortezomib therapy. Medical Oncology 2019;36:75

• Iriyama N, Yoshino Y, Yuan B, Horikoshi A, Hirabayashi Y, Hatta Y, Toyoda H, Takeuchi J: Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. Journal of Hematology and Oncology, 5:1, 2012.
• Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H: Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-First study of Kanto CML Study Group. American Journal of Hematology, 90:282-287, 2015.
• Iriyama N, Hatta Y, Takei M: Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes. Cancer Medicine, 5:3223-3234, 2016.